Palbociclib Clinical Trials

43 actively recruiting trials across 19 locations

Also known as: 571190-30-2, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)-, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, 6-acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one, C24H29N7O2 +10 more

Pipeline

Early 1: 1Phase 1: 8Phase 2: 12Phase 3: 7Phase 1/2: 12

Top Sponsors

Hoffmann-La Roche4
AstraZeneca3
Pfizer2
National Cancer Institute (NCI)2
Eli Lilly and Company2

Indications

Cancer43
Breast Cancer24
Metastatic Breast Cancer5
Advanced Solid Tumors3
Recurrent Malignant Female Reproductive System Neoplasm2

Other15 trials

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC

Phase 2

A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

Phase 1/2

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

N/A

A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

Phase 1/2

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Phase 2

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Phase 3

Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors

Phase 1/2

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Phase 1

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction

Phase 2

Pilot Trial for Treatment of Recurrent Glioblastoma

Early 1

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Phase 1/2

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Phase 2

The Drug Rediscovery Protocol (DRUP Trial)

Phase 2

Birmingham, Alabama5 trials

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

The Kirklin Clinic of UAB Hospital

Phase 3

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

University of Alabama at Birmingham Comprehensive Cancer Center

Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Duarte, California3 trials

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

City of Hope

Phase 1/2

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

City of Hope

Phase 1/2

Study of INCB123667 in Subjects With Advanced Solid Tumors

City of Hope Medical Center

Phase 1

Tucson, Arizona2 trials

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Research Site

Phase 3

DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

University of Arizona Cancer Center

Phase 2

Los Angeles, California2 trials

First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Ellison Clinic at Saint John's

Phase 1/2

SNV4818 in Participants With Advanced Solid Tumors

The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate

Phase 1/2

Boston, Massachusetts2 trials

A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma

Brigham and Women's Hospital

Phase 2

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Massachusetts General Hospital

Phase 2

Daphne, Alabama1 trial

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Southern Cancer Center

Phase 3

Dothan, Alabama1 trial

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

Dothan Hematology and Oncology

Phase 1/2

Anchorage, Alaska1 trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Alaska Oncology and Hematology

Phase 3

Chandler, Arizona1 trial

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Ironwood Cancer & Research Centers

Phase 3

Gilbert, Arizona1 trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Research Site

Phase 3

Scottsdale, Arizona1 trial

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

HonorHealth

Phase 1

Stanford, California1 trial

Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)

Lucile Packard Children's Hospital Stanford

Phase 1

New Haven, Connecticut1 trial

Study of AVZO-021 in Patients With Advanced Solid Tumors

Yale Cancer Center

Phase 1/2

Washington D.C., District of Columbia1 trial

Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer

Georgetown University

Phase 2

Iowa City, Iowa1 trial

Palbociclib and Pembrolizumab in Sarcoma

University of Iowa Hospitals & Clinics

Phase 1

St Louis, Missouri1 trial

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Research Site

Phase 1/2

Basking Ridge, New Jersey1 trial

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Phase 1/2

Chapel Hill, North Carolina1 trial

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Lineberger Comprehensive Cancer Center

Phase 1

Philadelphia, Pennsylvania1 trial

Tazemetostat and Palbociclib With CPX-351for R/R AML

Thomas Jefferson University Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.